Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 3/20 | 0.72 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.49 |
| ▸ | PRKCG | P05129 | 1/20 | 0.49 |
| ▸ | PRKCB | P05771 | 1/20 | 0.49 |
| ▸ | PRKCA | P17252 | 1/20 | 0.49 |
| ▸ | PRKCH | P24723 | 1/20 | 0.49 |
| ▸ | PRKCI | P41743 | 1/20 | 0.49 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.49 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.49 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.49 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.49 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.49 |
| ▸ | USP7 | Q93009 | 1/20 | 0.49 |
| ▸ | USP21 | Q9UK80 | 1/20 | 0.49 |
| ▸ | PARP10 | Q53GL7 | 11/20 | 0.46 |
| ▸ | PARP1 | P09874 | 10/20 | 0.46 |
| ▸ | PARP11 | Q9NR21 | 7/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.46 |
| ▸ | RAF1 | P04049 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aldisin SCHEMBL7844916 | 0.84 | MAP2K1 (1.00) | MAP2K1PRKD3PRKCGPRKCBPRKCA | |
| SCHEMBL980230 | 0.78 | MAP2K1 (0.58) | MAP2K1PRKD3PRKCGPRKCBPRKCA | |
| SCHEMBL21305078 | 0.76 | MAP2K1 (0.61) | MAP2K1PRKD3PRKCGPRKCBPRKCA | |
| SCHEMBL15468004 | 0.71 | MAP2K1 (0.60) | MAP2K1PRKD3PRKCGPRKCBPRKCA | |
| SCHEMBL3296103 | 0.71 | PARP11 (0.64) | MAP2K1PARP10PARP1PARP11PDPK1 | |
| Formic Acid SCHEMBL25205058 | 0.71 | MAP2K1 (0.50) | MAP2K1PRKD3PRKCGPRKCBPRKCA | |
| SCHEMBL22313400 | 0.69 | PARP11 (0.62) | MAP2K1PARP10PARP1PARP11PDPK1 | |
| SCHEMBL13222116 | 0.69 | MAP2K1 (0.62) | MAP2K1PRKD3PRKCGPRKCBPRKCA | |
| SCHEMBL116223 | 0.67 | — | — | |
| SCHEMBL6773859 | 0.67 | MAP2K1 (0.50) | MAP2K1PARP10PARP1PARP11PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6713634-B2 | SEROTONIN RECEPTOR ANTAGONIST | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2004-03-30 | — | — | US | disclosed |
| US-20030166926-A1 | Pyrroloazepine derivatives | SUNTORY LIMITED (JP) | 2003-09-04 | — | — | US | disclosed |
| EP-0915881-B1 | PYRROLOAZEPINE COMPOUNDS | SUNTORY LTD (JP) | 2003-01-08 | — | — | EP | disclosed |
| US-6489473-B2 | FOR THERAPY AND PROPHYLAXIS OF ISCHEMIC HEART DISEASES SUCH AS ANGINA PECTORIS, ARRHYTHMIA, MYOCARDIAL INFARCTION, CONGESTIVE HEART FAILURE, CEREBRAL INFARCTION AND CEREBRAL SEQUELAE AFTER SUBARACHNOID HEMORRHAGE, HYPERTENSION | SUNTORY LIMITED (JP) | 2002-12-03 | — | — | US | disclosed |
| US-20020072515-A1 | Pyrroloazepine derivatives | SUNTORY LIMITED (JP) | 2002-06-13 | — | — | US | disclosed |
| EP-0807632-B1 | PYRROLOAZEPINE DERIVATIVES | SUNTORY LTD (JP) | 2002-04-17 | — | — | EP | disclosed |
| US-6258805-B1 | TREATMENT OF BRAIN DISORDERS AND HYPERTENSION | SUNTORY LIMITED (JP) | 2001-07-10 | — | — | US | disclosed |
| US-6211362-B1 | CHEMICAL INTERMEDIATE FOR DRUGS | SUNTORY LIMITED (JP) | 2001-04-03 | — | — | US | disclosed |
| US-6187772-B1 | Pyrroloazepine compounds | SUNTORY LIMITED (JP) | 2001-02-13 | — | — | US | disclosed |
| US-5962448-A | Pyrroloazepine derivatives | SUNTORY LIMITED (JP) | 1999-10-05 | — | — | US | disclosed |
| EP-0915881-A1 | PYRROLOAZEPINE COMPOUNDS | SUNTORY LIMITED (JP) | 1999-05-19 | — | — | EP | disclosed |
| WO-1998041527-A1 | PYRROLOAZEPINE COMPOUNDS | SUNTORY LIMITED (JP) | 1998-09-24 | — | — | WO | disclosed |
| EP-0807632-A1 | PYRROLOAZEPINE DERIVATIVES | SUNTORY LIMITED (JP) | 1997-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072515-A1 | Pyrroloazepine derivatives | TPH2, HTR2A, HTR2C | MAP2K1 2540/4885PRKD3 1046/4885PRKCG 1541/4885 |
| US-20030166926-A1 | Pyrroloazepine derivatives | TPH2, HTR2A, HTR2C | MAP2K1 2371/4885PRKD3 1072/4885PRKCG 1561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.